Loading
AT
Adaptimmune Therapeutics PLC Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Wood Gavin, was filed 23 May 2022.
Adaptimmune Therapeutics PLC: what insiders have been doing
Adaptimmune Therapeutics PLC, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of Adaptimmune Therapeutics PLC in twelve months, the latest record being from 3 September 2025.
Looking back to 2016, when coverage begins, insiders filed 90 purchases and 132 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
247
Thresholds
n/a
Buy Volume
€359M
90 ops. · all time
Sell Volume
€28M
132 ops. · all time
Who traded when
BuySaleWilliam C. Bertrand Jr.5 sales
Adrian Rawcliffe4 sales
Elliot Norry4 sales
John Lunger4 sales
EcoR1 Capital, LLC3 sales
Ali Behbahani2 sales
+2 other insiders
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$153.3M
Net income-US$61M-39.8% margin
Last declaration on 3 September 2025
Declarations247 total
96,000 shares@ US$0.00997.1% of flowOrdinary Shares with a nominal value of GBP0.001 per shareSEC:0001104659-25-087085:0
207,000 shares@ US$0.01012.1% of flowOrdinary Shares with a nominal value of GBP0.001 per shareSEC:0001104659-25-085820:0
4,828,206 shares@ US$0.01123.2% of flowOrdinary Shares with a nominal value of 0.001 GBP per shareSEC:0000950170-25-110254:0
14,671,794 shares@ US$0.01276.8% of flowOrdinary Shares with a nominal value of 0.001 GBP per shareSEC:0000950170-25-110254:1
2,687,460 shares@ US$0.10123.9% of flowOrdinary SharesSEC:0000935836-25-000476:1
27,433,338 shares@ US$0.102141.0% of flowOrdinary SharesSEC:0000935836-25-000476:2
33,931,740 shares@ US$0.1125100.0% of flowOrdinary SharesSEC:0000935836-25-000476:0
30,601 shares@ US$0.58087.9% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-004605:0
5,584 shares@ US$0.58087.4% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-004608:0
5,584 shares@ US$0.58083.7% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-004606:0
5,584 shares@ US$0.58083.8% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-004607:0
4,268 shares@ US$0.58793.0% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-003768:0
4,268 shares@ US$0.58792.9% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-003765:0
12,539 shares@ US$0.58793.3% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-003775:0
4,268 shares@ US$0.58795.8% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-003771:0
12,991 shares@ US$0.57488.5% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-003774:0
5,471 shares@ US$0.58791.1% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-003765:1
9,803 shares@ US$0.57481.8% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-003765:2
5,471 shares@ US$0.58791.7% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-003768:1
9,803 shares@ US$0.57482.9% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-003768:2
8,124 shares@ US$0.58794.4% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-003771:1
9,803 shares@ US$0.57485.1% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-003771:2
17,934 shares@ US$0.58790.8% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-003775:1
29,096 shares@ US$0.57481.2% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-003775:2
24,531 shares@ US$0.9324.9% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-24-072874:0
25 of 247 declarations
About Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics PLC is a specialized biopharmaceutical company focused on cell therapy for solid tumors. The company is listed in the United States on the NASDAQ market under the ticker ADAP, and it operates with a transatlantic footprint: its corporate headquarters are in Abingdon, Oxfordshire, United Kingdom, while its U.S. operations have long been anchored in Philadelphia, Pennsylvania, United States. Adaptimmune was founded in 2014 as part of a corporate restructuring and was built around a proprietary T-cell receptor (TCR) platform designed to detect tumor antigens that are difficult to reach with traditional oncology approaches. In equity terms, it remains a niche, innovation-driven biotech with high clinical and commercial optionality, but also high execution risk.
The company’s core business is the development and commercialization of engineered autologous T-cell therapies. Its first commercial product, TECELRA (afamitresgene autoleucel), received U.S. FDA accelerated approval in August 2024 for certain adults with advanced or metastatic synovial sarcoma, making it the first approved engineered T-cell therapy for a solid tumor. That approval is strategically important because it moves Adaptimmune from a purely development-stage story into a commercial-stage cell therapy company. Alongside TECELRA, the pipeline includes programs directed at MAGE-A4, PRAME, and CD70, with a mix of clinical, preclinical, and platform assets. The strategic ambition is to leverage the company’s TCR know-how not only in autologous therapies but also in broader allogeneic and off-the-shelf cell therapy opportunities.
Read moreShow less
From a competitive standpoint, Adaptimmune operates in one of the most technically challenging areas of oncology. Its main differentiation lies in its TCR platform, which is designed to target intracellular antigens and therefore opens up a broader set of solid-tumor targets than conventional cell therapies. This gives the company a credible scientific niche versus larger immuno-oncology peers, CAR-T developers, and well-capitalized biotech competitors. At the same time, the company still faces the typical constraints of a young cell-therapy franchise: manufacturing complexity, reimbursement uncertainty, patient identification, and the need to build a durable commercial footprint.
Recent developments have been important. In 2025, Adaptimmune reported accelerating TECELRA launch momentum, with patient apheresis activity and an expanding treatment network. The company also said it was progressing a rolling BLA submission for lete-cel, while continuing cost-reduction efforts and a corporate restructuring. Another key recent event was the voluntary delisting of its ADSs from NASDAQ in late 2025, which matters for liquidity, investor access, and trading dynamics. For investors, Adaptimmune remains a high-beta healthcare name whose valuation is likely to be driven by TECELRA adoption, pipeline execution, and the company’s ability to translate its TCR platform into sustained commercial success in the United States.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
